Nimbus Therapeutics

Nimbus hopes to strike thrice
Nimbus hopes to strike thrice
EP Vantage
Nimbus Therapeutics
NASH
firsocostat
Flag link:
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
Flag link:
10 clinical trials to watch in the first half of 2023
10 clinical trials to watch in the first half of 2023
BioPharma Dive
clinical trials
Alzheimer's disease
obesity
Huntington's disease
M&A
AstraZeneca
Daiichi Sankyo
Nimbus Therapeutics
Takeda
Eli Lilly
Sanofi
Regeneron
Moderna Therapeutics
Gilead Sciences
Pfizer
Roivant
Alnylam
uniQure
Flag link:
Takeda wagers up to $6B on Nimbus’ TYK2 drug
Takeda wagers up to $6B on Nimbus’ TYK2 drug
BioPharma Dive
Takeda
Nimbus Therapeutics
autoimmune diseases
NDI-034858
Flag link:
Nimbus on cloud 9 as psoriasis data support taking rival to Bristol Myers' Sotyktu into phase 3
Nimbus on cloud 9 as psoriasis data support taking rival to Bristol Myers' Sotyktu into phase 3
Fierce Biotech
Nimbus Therapeutics
Sotyktu
Bristol Myers Squibb
clinical trials
NDI-034858
Flag link:
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
Nimbus raises $125M to advance rival to Bristol Myers’ new psoriasis drug
BioPharma Dive
Nimbus Therapeutics
psoriasis
Bristol Myers Squibb
Sotyktu
Flag link:
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Next-gen psoriasis drug rivalry between Bristol Myers and Nimbus spills into a legal battle
Endpoints
Bristol Myers Squibb
Celgene
Nimbus Therapeutics
psoriasis
deucravacitinib
Flag link:
Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Celgene bags option on Nimbus' anticancer HPK1 inhibitor
Fierce Biotech
Celgene
Nimbus Therapeutics
HPK1 inhibitors
Flag link: